This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Veracyte stock in Canada | $42.82

Own Veracyte shares in just a few minutes.


Fact checked

Veracyte, Inc is a biotechnology business based in the US. Veracyte shares (VCYT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $42.82 – an increase of 3.28% over the previous week. Veracyte employs 354 staff and has a trailing 12-month revenue of around $112.5 million.

How to buy shares in Veracyte

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VCYT in this case.
  5. Research Veracyte shares. The platform should provide the latest information available.
  6. Buy your Veracyte shares. It's that simple.

How has Coronavirus impacted Veracyte's share price?

Since the stock market crash in March caused by coronavirus, Veracyte's share price has had significant positive movement.

Its last market close was $42.82, which is 41.06% up on its pre-crash value of $25.24 and 208.06% up on the lowest point reached during the March crash when the shares fell as low as $13.9.

If you had bought $1,000 worth of Veracyte shares at the start of February 2020, those shares would have been worth $625.30 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,589.05.

Veracyte share price

Use our graph to track the performance of VCYT stocks over time.

Veracyte shares at a glance

Information last updated 2020-10-20.
Latest market close $42.82
52-week range $13.9 - $44.64
50-day moving average $34.4097
200-day moving average $29.4707
Wall St. target price $37.4
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.288

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Wealthsimple Trade
Stocks, ETFs
Buy and sell thousands of US and Canadian stocks and ETFs commission-free with Wealthsimple Trade.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
CI Direct Investing (formerly WealthBar)
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Automatic bank withdrawals
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Direct deposit, Bank transfer, Automatic bank withdrawals
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Wealthsimple Invest
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Minimum US$25
Shares Desktop, Web Trading, Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on

Compare up to 4 providers

Is it a good time to buy Veracyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Veracyte price performance over time

Historical closes compared with the last close of $42.82

1 week (2020-11-27) -19.51%
1 month (2020-11-05) 1.93%
3 months (2020-09-04) 34.95%
6 months (2020-06-05) 64.38%
1 year (2019-12-05) 42.78%
2 years (2018-12-04) 254.76%
3 years (2017-12-05) 574.33%
5 years (2015-12-04) 512.59%

Veracyte financials

Revenue TTM USD$112.5 million
Gross profit TTM USD$83.8 million
Return on assets TTM -7.55%
Return on equity TTM -13.73%
Profit margin -27.49%
Book value $4.483
Market capitalisation USD$2.4 billion

TTM: trailing 12 months

How to short and sell Veracyte shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VCYT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 3.5 million Veracyte shares held short by investors – that's known as Veracyte's "short interest". This figure is 0.7% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting Veracyte shares can be evaluated.

Veracyte's "short interest ratio" (SIR)

Veracyte's "short interest ratio" (SIR) is the quantity of Veracyte shares currently shorted divided by the average quantity of Veracyte shares traded daily (recently around 444928.00511509). Veracyte's SIR currently stands at 7.82. In other words for every 100,000 Veracyte shares traded daily on the market, roughly 7820 shares are currently held short.

However Veracyte's short interest can also be evaluated against the total number of Veracyte shares, or, against the total number of tradable Veracyte shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Veracyte's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Veracyte shares in existence, roughly 60 shares are currently held short) or 0.0611% of the tradable shares (for every 100,000 tradable Veracyte shares, roughly 61 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Veracyte.

Find out more about how you can short Veracyte stock.

Veracyte share dividends

We're not expecting Veracyte to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Veracyte share price volatility

Over the last 12 months, Veracyte's shares have ranged in value from as little as $13.9 up to $44.64. A popular way to gauge a stock's volatility is its "beta".

VCYT.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Veracyte's is 0.6233. This would suggest that Veracyte's shares are less volatile than average (for this exchange).

Veracyte overview

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site